Extended Data Fig. 2: Characterization of peptide treatment on GBM cell growth in vitro and tumor growth in vivo.
a. Co-IP shows EAG2-Kvβ2 interaction in G411 GBM cells treated with TAT, K59-78TAT, K90-114, or K90-114TAT. 3 biologically independent experiments were performed. b. Cell number, microtube number per cell, and microtube length of G489 GBM cells, which are co-cultured with neurons, after TAT, K59-78TAT, K90-114, or K90-114TAT treatment. Sample size (from left to right): n = 31, 42, 31, 43, 50, 52, 33, 41, 78, 146, 116, 49 cells examined over 3 independent experiments. Adjusted P value was calculated by Tukey’s multiple comparisons test (n.s. means not significant, P > 0.05). Error bars, mean ± s.e.m. Cell number and microtube length of K59-78TAT and K90-114TAT treated cells are also shown in Fig. 5b for easier data interpretation. c. Representative images and quantification of tumor areas of G411 xenograft tumors treated for 7 days with K59-78TAT or K90-114TAT. n = 15 samples examined from 5 biologically independent animals. P values, two-sided unpaired t-test. Error bars, mean ± s.e.m. d. Bioluminescence images and survival comparison of G411 GBM-bearing mice treated with K59-78TAT or K90-114TAT at various dosages. P values, log-rank test. Each P value was generated individually by comparing to K59-78TAT. e. Bioluminescence images and survival comparison of G411 GBM-bearing mice treated with TAT, K90-114, or randomized K90-114 TAT. K59-78TAT survival curve is derived from Fig. 5d. P values, log-rank test.
